Clinical trials: Preeclampsia (PE) Risk
Cardiovascular Biomarkers, Preeclampsia (PE) Risk
A Study to Find and Confirm Blood-based Markers (Called Proteins) That May Show Early Heart Changes in Women With Preeclampsia, Even Before Symptoms Appear, and the Use of Heart Ultrasound (Echocardiography) to Look at Patterns of How the Heart Changes During Pregnancy in Women With Preeclampsia
The goal of this study is to find and confirm blood-based markers (called proteins) that may show early heart changes in women with preeclampsia, even before symptoms appear.
- Conditions
- Cardiovascular Biomarkers, Preeclampsia (PE) Risk, Preeclampsia (PE)
- Trial name
- PRECISE (NCT07463898)
- Testing
- No Intervention: Observational Cohort
- Where
- Nigeria
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Low Birth Weight, Small for Gestational Age (SGA)
Improving Aspirin Prescription Rates in Outpatient Clinic
Ρrееςlаmpѕia is a syndrome characterised by the new onset of hуреrtеnѕion plus proteinuria, end-organ dysfunction, or both after 20 weeks of gestation. It complicates 3-5% of pregnancies.
- Conditions
- Low Birth Weight, Small for Gestational Age (SGA), Preeclampsia (PE), Prevention &Amp; Control
- Trial name
- NCT06694233
- Testing
- Aspirin prescription on outpatient basis
- Where
- Kuwait
- Volunteers
- 300 people
- Sponsor
- Cairo University
Preeclampsia (PE) Risk, Oocyte Donation
Preeclampsia and Defective Placentation in Oocyte Donation: Importance of HLA-C and KIR
The IMMUN-OR study aims to study HLA-C/KIR combinations when looking at the risk of development of preeclampsia (PE) in pregnancies after oocyte donation.
- Trial name
- IMMUN-OR (NCT07178652)
- Volunteers
- 2,325 people
- Sponsor
- Universitair Ziekenhuis Brussel